Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.

With Hims & Her's main source of growth set to be extinguished, Citi analysts said its full-year guidance appears "aspirational." ...

Roller-coaster healthcare stock Hims & Hers Health ( HIMS -1.34%), whose stock got devastated last week by worries that it ...

The final pivot is to Hims & Hers, with its affordable “doctor-trusted” treatments, “formulated in the USA” as part of a custom treatment plan. People smile and brandish med vials as the ...

Telehealth company Hims & Hers Health (HIMS) witnessed a major dip in its stock recently despite reporting 95% revenue growth ...

Hims & Hers (HIMS) stock is sinking 20% today after ... Eli Lilly disclosed today that it had started selling 7.5 milligram and 10 milligram vials of Zepbound, its popular weight-loss drug ...

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operation | Hims & Hers ...

Step right up, ladies and gentlemen, and welcome to the hottest new spot in town: The Weight-Loss Casino! Here, you don’t ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase, and achieved $126 million in GAAP net income. The company’s subscriber base reached 2.2 million ...

Hims & Hers (HIMS) made a killing last year selling ... which lets Ro offer its members cheaper Zepbound in vials rather than the standard auto-injector pens. However, he added, that there is ...

Apostrophe, a skin care telehealth brand headquartered in the Bay Area, is shutting down after almost four years under the Hims & Hers corporate umbrella. The skin care company, founded in ...

The move: Hims & Hers stock plunged by as much as 27% on Tuesday ... announced on Tuesday that it would lower the price of its drugs in vial form for people paying out of pocket rather than ...